Marjan Farid, MD
Ophthalmic Plastic and Reconstructive Surgery · Irvine, CANPI 1275589756
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $546,604 of the $742,271 with a category attached, or 73.6%. 30 manufacturers reported payments, led by Johnson & Johnson Surgical Vision, Inc. at 38.2% of the total. Among ophthalmic plastic and reconstructive surgery clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 587 payments — averaging $1264.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson Surgical Vision, Inc.$283K
- Alcon Research LLC$63K
- Oyster Point Pharma, Inc.$59K
- Bausch & Lomb Americas Inc.$59K
- AbbVie$51K
- Alcon$41K
- plus $187K from 24 others
Across 23 payments — averaging $5248.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Oyster Point Pharma, Inc.$76K
- Regeneron$29K
- Johnson & Johnson Surgical Vision, Inc.$15K
- Kowa Research Institute, Inc.$1K
What the payments were for
- Consulting fees$546,60474%
- Speaking & faculty fees$156,69121%
- Travel & lodging$21,6193%
- Food & beverage$17,3572%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson Surgical Vision, Inc. | 151 | $283,262 |
| Alcon Research LLC | 15 | $62,914 |
| Oyster Point Pharma, Inc. | 59 | $59,327 |
| Bausch & Lomb Americas Inc. | 71 | $58,523 |
| AbbVie(2 entities) | 63 | $50,785 |
| Alcon | 23 | $40,873 |
| Tarsus Pharmaceuticals, Inc. | 17 | $36,101 |
| Dompe US, Inc. | 36 | $34,159 |
| Novartis | 21 | $23,213 |
| Biotissue Holdings Inc. | 15 | $17,233 |
| Kala Pharmaceuticals, Inc. | 21 | $16,588 |
| Carl Zeiss Meditec, Inc. | 23 | $14,109 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 13 | $11,622 |
| Glaukos Corporation | 13 | $10,676 |
| Shire North American Group Inc | 4 | $5,470 |
| Sight Sciences, Inc. | 7 | $4,859 |
| Sun Pharmaceutical Industries Inc. | 5 | $3,694 |
| Eyevance Pharmaceuticals LLC | 4 | $2,311 |
| Eyepoint US, Inc. | 2 | $1,819 |
| Harrow Eye, LLC | 2 | $1,638 |
| Johnson & Johnson Vision Care, Inc. | 3 | $822 |
| Beaver-visitec International, Inc. | 2 | $769 |
| Rxsight Inc | 9 | $707 |
| Katena Products, Inc. (dba Corza Medical) | 1 | $250 |
| Carl Zeiss Meditec USA, Inc. | 1 | $163 |
| Apellis Pharmaceuticals, Inc. | 1 | $113 |
| Mallinckrodt Hospital Products Inc. | 1 | $100 |
| Ocular Therapeutix, Inc. | 2 | $81 |
| Amgen | 1 | $50 |
| Quidel Corporation | 1 | $40 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Compact Intuitiv$128,004
- Healon Duet Pro$128,004
- IFS ADVANCED FEMTOSEC LASER$128,004
- TRYPTYR$63,117
- TYRVAYA$58,535
- Catalys Laser System$50,966
- Healon Viscoelastics$50,575
- COMPACT INTUITIV Phacofragmentation System$47,575
- XIIDRA$37,702
- Oxervate$33,750
- Tecnis 1-piece IOL$29,401
- Tecnis IOL$26,868
- XDEMVY$25,715
- Tecnis Multifocal Family of 1-piece IOLS$22,279
- Tecnis Symfony IOL$21,419
- Tecnis 3-piece IOL$21,372
- Tecnis Symphony IOL$21,372
- Tecnis Symphony Toric IOL$21,372
- Crystalens Accommodating IOL (AT-52AO)$19,892
- EYSUVIS$19,450
How this compares
$742,271 in reported general payments places this provider in the 95th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.
See all ophthalmic plastic and reconstructive surgery providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XiidraLifitegrast | 108 | $98,538 |
| RestasisCyclosporine | 62 | $55,663 |
| XdemvyLotilaner | 28 | $50,000 |
| MieboPerfluorohexyloctane/Pf | 39 | $32,208 |
| IlevroNepafenac | 48 | $17,637 |
| VevyeCyclosporine | 19 | $13,525 |
| Cyclosporine | 41 | $13,278 |
| Prednisolone Acetate | 358 | $11,784 |
| Loteprednol Etabonate | 73 | $9,521 |
| Mycophenolate Mofetil | 19 | $8,553 |
| MoxifloxacinMoxifloxacin Hcl | 289 | $6,754 |
| LumiganBimatoprost | 11 | $3,559 |
| ValacyclovirValacyclovir Hcl | 27 | $3,313 |
| Difluprednate | 24 | $2,796 |
| Pred FortePrednisolone Acetate | 14 | $2,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $58,523 | $130,745147 claims |
| AbbVieRestasis, Lumigan | $50,785 | $59,22273 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $36,101 | $50,00028 claims |
| NovartisIlevro | $23,213 | $17,63748 claims |
| Harrow Eye, LLCVevye | $1,638 | $13,52519 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $11,622 | $9,52173 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 50 ophthalmic plastic and reconstructive surgery providers in California.
Other ophthalmic plastic and reconstructive surgery in Irvine
- Jeremiah TaoIrvine$12K
- Lilangi EdiriwickremaIrvine$436
- William ChenIrvine$191
- Jeffrey JosephNewport Beach$292K
- Sandy Zhang-NunesLos Angeles$149K
- Soheab UgradarLos Angeles$131K
- Andrea KosslerStanford$91K
- Nicolas BiroWest Covina$76K
- Joseph ChangBakersfield$74K
- Anupam JayaramMenlo Park$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.